BioCentury
ARTICLE | Company News

FDA approves Procysbi for nephropathic cystinosis

May 1, 2013 12:39 AM UTC

FDA approved an NDA from Raptor Pharmaceutical Corp. (NASDAQ:RPTP) for Procysbi ( RP103) to treat nephropathic cystinosis in patients aged six and older. The approval triggers a $25 million tranche to...